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Impact of different antithrombotics 
on the microcirculation and viability 
of perforator-based ischaemic skin 
flaps in a small animal model
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The effects of antithrombotic drugs on random and free flap survival have been investigated in the past, 
but the experimental and clinical results are not in agreement. A perforator-based critical ischaemia 
model was used to evaluate the effects of different perioperatively administered pharmaceutical 
agents on tissue ischaemia and to assess the potential additional haemorheological or vasodilative 
effects of antithrombotics on flap microcirculation. Combined laser Doppler flowmetry and remission 
spectroscopy revealed an increase in certain microcirculation parameters in most groups in comparison 
with saline controls, and these changes correlated with flap survival. Clopidogrel and hirudin 
significantly improved the amount of viable flap tissue in comparison with controls, while unfractioned 
heparin had a negative effect on flap survival. Low molecular weight heparin, aspirin, pentoxifylline, 
and hydroxyethyl starch had no impact on the amount of viable flap tissue. A higher complication 
rate was observed in all experimental groups, but only clopidogrel had a negative impact on the 
flap viability. Our results add to the body of evidence supporting the conclusion that perioperative 
antithrombotic treatment improves flap survival. Clopidogrel and hirudin are effective pharmacological 
agents that significantly increased the viability of perforator-based skin flaps in rats, but at a higher risk 
of postoperative bleeding.
Flap necrosis is an important complication in the field of plastic and reconstructive surgery. The key reasons 
for flap necrosis are usually attributed to intrinsic haemodynamic problems associated with the flap, including 
arterial flow insufficiency, venous congestion, or a combination thereof. Regardless of the cause, flap necrosis 
may require multiple revision surgeries with all of the associated risks, and usually results in prolonged wound 
care and hospitalization, work loss, unsatisfactory results, a reduced quality of life and increased medical costs1,2.
Numerous strategies have been proposed to avoid flap ischaemia, including surgical technique refinement, 
patient selection and perioperative planning3, tissue warming2 and the use of numerous pharmacological agents, 
such as vasodilators, anti-inflammatory drugs, sympatholytics, haemorheological agents and antithrombotics4–15. 
Encouraged by a body of evidence from animal experiments showing a positive impact of antithrombotic drugs 
on the patency rate of anastomoses in microvascular free flaps4–15 and on the survival of random1,4,5,16,17 and pedi-
cle flaps18, many reconstructive surgeons today rely on peri- and postoperative antithrombotics19–23. However, 
the clinical usefulness of this practice has been debated in the recent past24. Antithrombotic treatment also has a 
higher risk of postoperative bleeding, an important complication that is rarely taken into account in animal stud-
ies investigating the effect of antithrombotics on flap viability. In most animal models used to study this subject, a 
thrombogenic environment is induced, e.g., using venous “tuck” or “crush-avulsion-injury” models25,26. However, 
these thrombogenic conditions do not correspond well with the clinical situation, which may explain the discrep-
ancy of the effectiveness of antithrombotic drugs observed between animal experiments and the clinical setting24.
The aim of this study was to investigate the effects of different antithrombotic agents on flap ischaemia. To 
better reflect the clinical situation, a critical ischaemia model27 was used instead of creating a thrombogenic 
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environment. Postoperative complications were documented and scored according to their incidence and 
severity.
Apart from the well-studied antithrombotic effects, additional anti-inflammatory4, vasodilative28,29 and/or 
haemorheological effects5 have been assumed for numerous antithrombotic agents such as acetylsalicylic acid, 
heparin and clopidogrel. Instead of limiting the focus of our study to the vessel patency6,7,9–11,14,30–34, another 
advantage of the surgical model used in this study was that it was possible to monitor the microcirculation 
changes in the skin and assess the actual clinical outcome (flap vitality), thereby further assessing possible addi-
tional drug effects.
Results
All 108 recipient rats survived the postoperative period and tolerated the anaesthesia and operation well.
Microcirculation changes. The changes in the microcirculation system are depicted in Fig. 1. After raising 
the flap, a significant decrease in the blood flow, velocity and oxygen saturation and an increase in the haemoglo-
bin level could be observed in all groups in comparison with the baseline values. The blood flow parameters (flow 
and velocity) tended to be higher in most experimental groups in comparison with the saline controls after the 
flap was raised. Hydroxyethyl starch (HES) and acetylsalicylic acid (ASA) seemed to have a positive influence on 
the blood flow in the microcirculation system. After seven days, however, this effect was less evident. The micro-
circulation parameters tended to recover in most groups with the exception of the groups administered saline 
solution, unfractioned heparin, low molecular weight heparin (clexane) and HES. The highest flow and velocity 
values were observed after the administration of clopidogrel or pentoxifylline (Px I). With the exception of saline 
solution and lepirudin, a hirudin derivative, the haemoglobin concentration returned to normal by day 7. The 
oxygen saturation tended to recover in the groups treated with clopidogrel, unfractioned heparin, pentoxifylline 
and HES, but did not reach the base values in any of the groups. Due to high interindividual fluctuations due to 
the method used35, no statistical comparisons between groups were performed.
Flap viability on day 7 and postoperative complications. The mean vitality rates are depicted in 
Fig. 2. The clopidogrel (median = 89.67, mean = 63.53 ± 38.16, P = 0.0003) and lepirudin (median = 67.50, 
mean = 58.03 ± 23.10, P = 0.003) groups showed statistically significantly larger vital flap areas in comparison 
with saline controls (median = 16.62, mean = 18.87 ± 10.95, Table 1). ASA, clexane and pentoxifylline (the latter 
Figure 1. Impact of various pharmaceutical agents on the microcirculation. Depicted are the mean laser 
spectrophotometric values for the oxygen saturation (SO2 in percent), haemoglobin levels (Hb in AU), blood 
velocity (in AU) and blood flow (in AU) over the course of the experiment. Measurements were conducted 
preoperatively (light), after raising the flap (medium) and on day 7 (dark). Error bars indicate the standard 
error. Abbreviations: (NaCl) saline solution, (ASA) acetylsalicylic acid, (Clop) clopidogrel, (Hep) heparin,  
(Clex) clexane, (Lep) lepirudin, (Px) pentoxifylline, and (HES) hydroxyethyl starch.
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only if administered 14 days prior to surgery) also showed a tendency to improve the flap survival in comparison 
with saline controls, but the differences were not statistically significant.
In the multivariate analysis, clopidogrel (P = 0.002) and lepirudin (P = 0.019) had a statistically signifi-
cant positive influence on flap survival, while heparin (P = 0.03) showed a negative influence on flap survival. 
Pentoxifylline I (P = 0.054) also tended to have a negative influence on flap survival, but this effect failed to reach 
statistical significance. The other groups showed no statistically significant impact on flap survival.
The incidence and severity of postoperative complications are depicted in Table 2. The development of necro-
sis was significantly correlated with all microcirculation parameters on day 7, but not the parameters measured 
immediately after raising the flap (Table 3). The risk of haematoma was increased in all experimental groups, with 
an incidence rate between 67% and 100%. The most frequent and severe cases were observed in the clopidogrel, 
clexane, lepirudin and HES groups (Table 2). The microcirculation parameters, however, were not affected by 
haematoma formation (Table 3). However, individual examination of each group indicated that the haematoma 
severity did have a statistically significant (negative) impact on flap viability, although only in the clopidogrel 
group (P = 0.031, r = − 0.621). Notable seromas were only observed if either HES or saline solution was admin-
istered (Table 2).
Discussion
A number of antithrombotic drugs have shown a positive effect on the free flap patency rate4–15 and viability 
of random1,4,5,16,17 and pedicle flaps18 in animal experiments. However, clinical studies often fail to confirm a 
statistically significant advantage of postoperative antithrombotic treatment24, and the clinical usefulness of this 
practice has therefore been debated in the recent past24. One important reason for the discrepancy between ani-
mal models and clinical studies may be that almost all animal studies have been conducted under a thrombogenic 
Figure 2. Impact of various pharmaceutical agents on the flap vitality. Box plot graph illustrating the amount 
of vital tissue (in percent) in the control group (saline solution, NaCl) and the experimental groups ((ASA) 
acetylsalicylic acid, (Clop) clopidogrel, (Hep) heparin, (Clex) clexane, (Lep) lepirudin, (Px) pentoxifylline, 
(HES) hydroxyethyl starch). The small circles indicate statistical outliers. Clopidogrel and lepirudin showed 
statistically significantly larger vital flap areas in comparison with saline controls.
NaCl ASA Clop Hep Clex Lep Px I Px II HES
NaCl 0.539 0.0003 > 0.999 0.637 0.003 > 0.999 0.112 0.998
ASA 0.175 0.699 > 0.999 0.489 0.761 0.995 0.933
Clop 0.0008 0.127 1.000 0.001 0.673 0.005
Hep 0.786 0.006 > 0.999 0.191 > 0.999
Clex 0.395 0.839 0.986 0.966
Lep 0.009 0.946 0.028
Px I 0.235 > 0.999
Px II 0.457
HES
Table 1.  Statistical analysis of the vitality rate. Statistical analysis of the vitality rates between all groups. An 
ordinary one-way ANOVA was used for the statistical analysis. Tukey’s multiple comparisons test was used 
to account for the problems associated with multiple testing. The adjusted two-tailed P values are provided. 
Abbreviations: (NaCl) saline solution, (ASA) acetylsalicylic acid, (Clop) clopidogrel, (Hep) heparin, (Clex) 
clexane, (Lep) lepirudin, (Px) pentoxifylline, (HES) hydroxyethyl starch. Statistically significant differences 
(P < 0.05) are marked in bold.
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environment24. Since these conditions do not closely resemble the clinical situation, it is likely that, although the 
influence of antithrombotics may not be significant in routine cases with low thrombogenic risks, their effect 
may be greater under thrombogenic conditions24. Differences observed between the outcomes of clinical and 
animal models may originate in the inadequacy of experimental models. To overcome this obstacle, we used a 
critical ischaemia model. The focus of our study was to assess the impact of different pharmaceutical agents on 
tissue ischaemia without creating thrombogenic conditions. A perforator flap model was chosen because it best 
resembles the anatomical aspects of a microvascular free flap, although (admittedly) without anastomosis (see 
limitations). At the same time, our model represents a critical ischaemia model comparable with a random flap 
model1,4,5,16,17, in which the amount of viable tissue correlates with the “anti-ischaemic” potential of the admin-
istered pharmaceutical agent27. The primary outcome parameter in our study was the amount of vital flap tissue 
seven days post-surgery. We feel that this approach to a small animal model more closely resembles clinical reality. 
Moreover, the complication rate and possible additional haemorheological effects apart from an antithrombotic 
effect could also be accounted for in our study. Only male animals were used to avoid a potential bias arising from 
fluctuations in the oestrus cycle, which can affect drug pharmacodynamics and pharmacokinetics36, coagulation37 
and haemodynamics38 and can even have an impact on postoperative bleeding complications39,40.
Our study supports the assumption that many antithrombotic drugs also have an additional rheological 
effect, as other authors have proposed14,15,41–45. As could be expected from the previous studies27,46,47, the anatom-
ical changes caused by raising a flap led to a temporary impairment in the microcirculation in all groups, with 
decreasing flow parameters and oxygen saturation. At the same time, rising haemoglobin levels were observed, 
indicating transient venous congestion. HES and ASA seemed to have had a positive influence on the blood flow 
in the microcirculation system directly after raising the flap, but this effect could not be observed after seven 
days. In comparison with saline controls, clopidogrel, clexane and pentoxifylline seemed to have had a positive 
influence on all microcirculation parameters on day 7. There was a strong negative correlation between the rate of 
necrosis and all microcirculation parameters on day 7. This finding indicates that in flaps with a high amount of 
necrotic tissue, the microcirculation in the (clinically) vital parts of the flap was also impaired. Further details on 
the influence of each pharmaceutical agent are discussed later in this paper.
Acetylsalicylic acid (ASA), or Aspirin®, irreversibly and non-selectively inhibits the COX-1 receptor, reducing 
the amount of thromboxane production that is essential for platelet aggregation. Apart from its common use in 
the treatment of coronary heart disease, ASA is also used in reconstructive microsurgery48. Shalom et al. noted 
that the well-known anti-inflammatory effects of ASA might be partly responsible for its positive effects on the 
survival of random skin flaps in rats4. Only ASA dosages (200 mg/kg body weight) had a positive impact on flap 
survival. In our study, an ASA dose of 25 mg/kg body weight led to increased vitality rates (38.1%) in comparison 
with saline controls (18.9%), but the difference failed to reach statistical significance. The dose used by Shalom 
et al. was approximately eight times higher than that used in our study, which would dramatically increase the 
potential risk of gastric ulcers or internal bleeding in the clinical setting. ASA had a positive initial impact on the 
microcirculation after the flap was raised, leading to higher flow and velocity values, but this effect was no longer 
evident after seven days.
Control Platelet Inhibitors Anticoagulants Rheologic Drugs
NaCl ASA Clop Hep Clex Lep Px I Px II HES
Necrosis 81.13 ± 10.95 61.90 ± 22.15 36.47 ± 14.93 78.84 ± 14.29 63.27 ± 29.26 41.97 ± 23.10 77.88 ± 26.38 53.80 ± 16.67 74.19 ± 16.58
Haematoma Incidence 4/12 8/12 11/12 11/12 12/12 12/12 11/12 10/12 12/12
Haematoma Severity (+ ) + + + + + + + + + + + + 
Seroma Incidence 9/12 7/12 6/12 0/12 0/12 1/12 6/12 1/12 9/12
Seroma Severity + (+ ) (+ ) − − − (+ ) − + 
Table 2.  Postoperative complications. The mean percentage of skin necrosis (± SD) and evidence of 
haematoma and/or seroma (Score: “−” = none, “(+ )” = very small, “+ ” = small, “+ + ” = moderate,  
“+ + + ” = large) on postoperative day 7. Abbreviations: (NaCl) saline solution, (ASA) acetylsalicylic acid, 
(Clop) clopidogrel, (Hep) heparin, (Clex) clexane, (Lep) lepirudin, (Px) pentoxifylline, (HES) hydroxyethyl 
starch.
SO2 day 0 Hb day 0 Flow day 0 Velocity day 0 SO2 day 7 Hb day 7 Flow day 7 Velocity day 7
Necrosis − 0.158 (0.102)
− 0.177 
(0.068) 0.026 (0.788) 0.012 (0.902) −0.326 (0.003) −0.227 (0.038) −0.437 (<0.0001) −0.431 (<0.0001)
Haematoma 0.031 (0.782) 0.086 (0.435) − 0.014 (0.896) − 0.100 (0.366)
Table 3.  Impact of postoperative complications on the microcirculation. Pearson’s correlation was used 
for the statistical analysis. The Pearson coefficient, r, and the two-tailed P values (in brackets) are provided. 
Abbreviations: (Day 0) the day of the operation after the flap was raised, (Day 7) postoperative day 7, (SO2) 
oxygen saturation, (Hb) haemoglobin level, (Flow) blood flow, (Velocity) blood flow velocity. The rates of both 
necrosis and haematoma were assessed on day 7. Not all comparisons made logical sense, and statistical tests 
were therefore not performed in these cases (empty boxes). Statistically significant differences (P < 0.05) are 
marked in bold.
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Clopidogrel, another commonly used platelet inhibitor, specifically inhibits the P2Y12 subtype of the 
ADP-receptor, which is important for platelet activation and the cross-linking of fibrin. Clopidogrel is a prodrug 
that is converted to its active metabolite after being metabolized by hepatic cytochrome enzyme P2C19. Due to 
variable oral absorption, the bioavailability shows high interindividual variability1. Clopidogrel led to signifi-
cantly higher patency rates in venous6 and arterial7 “tuck” models and significantly prolonged the time until a 
thrombus was formed in comparison with saline controls6. In rat random skin flap models, clopidogrel produced 
a significant increase in the survival rates1,28,29. Our perforator-based flap model corroborates these findings: with 
63.5% viable tissue (median = 89.7%), clopidogrel was associated with the highest flap survival in our study. The 
vitality rate was significantly higher in the clopidogrel group in comparison to the saline solution, pentoxifylline 
and HES groups.
While the prevention of platelet aggregation is the most probable cause of the improvement noted in the via-
bility of flaps, vasodilation, prevention of free O2 radicals and an effect on ischaemic reperfusion have also been 
discussed as possible mechanisms28,29. In fact, the microcirculation parameters were superior in the clopidogrel 
group in comparison with saline controls, indicating that an additional effect, due to vasodilatation or improved 
haemorheology, may have also played a role. In the logistic regression analysis, clopidogrel also had the highest 
impact on flap perfusion. However, with an incidence of 92%, haematoma formation was a problem in this study 
group. As the high median indicates, most flaps showed a very high amount of viable tissue, while few flaps 
became almost completely necrotic. These necrotic flaps all showed severe haematomas. The correlation analysis 
substantiates the suspicion that haematoma formation may have been responsible for flap necrosis in these cases. 
Based on the current literature and the results from this study, clopidogrel is likely to have a positive impact 
on flap survival. However, postoperative bleeding must be taken into consideration as a complication that can 
impede flap success.
Heparin, the glycosaminoglycan is the most commonly used anticoagulant49. Heparin also plays a role as an 
irrigant in microvascular surgery both in the unfractioned and low molecular weight forms50. While unfractioned 
heparin reduces the formation of fibrin clots by simultaneous inhibition of antithrombin III, thrombin and factor 
X, low-molecular-weight heparin (such as clexane) has a higher selectivity for factor X12. The vasodilative effect of 
heparin has also been discussed51. In experimental “crush-avulsion-injury” models, heparin increases the patency 
rate of anastomosed vessels9–11, and in high doses, even topical administration seems to effectively reduce sys-
temic effects and associated risks11. Statements regarding the effects of heparin on flap viability are diverse and 
contradictory in the literature. While some authors have observed a significant improvement of the flap viability 
in random skin flaps17,52 or venous congestion models53, other authors have not1,4. In our experimental model, 
heparin failed to show a significant impact on flap viability. Low molecular weight heparin (36.7%) tended to 
show better results than unfractioned heparin (21.2%), which had the least positive effect on flap vitality of all 
experimental groups. The better results obtained using clexane may be attributable to its superior dose-response 
relationship51. Due to its pharmacodynamics, unfractioned heparin is usually administered as a continuous infu-
sion clinically, which was not feasible in our animal model and may detract from the transferability of results. A 
positive effect on the microcirculation was not evident after heparin administration. Blood loss during surgery 
activates the coagulation system and induces hypercoagulability. Therefore, intraoperative heparin administra-
tion is considered to be protective. However, the initial administration of heparin is usually postponed until after 
the surgery is completed for fear of excessive intraoperative bleeding51. Systemic administration of heparin has 
often been associated with a higher risk of wound haematomas, which might impair flap perfusion and even lead 
to flap failure51,54. In this study, almost all animals treated with either unfractioned or low-molecular weight hep-
arin (clexane) showed varying degrees of haematomas, but this process had no influence on flap viability.
Hirudin, a fibrinolytic substance extracted from the saliva of leeches, is the most potent natural inhibitor of 
thrombin. It works without antithrombin III and even inhibits clot-bound thrombin55. Desirudin, a synthetic 
hirudin derivative, significantly increased the patency rate of rat femoral veins in comparison with saline solution 
after microvascular anastomosis using the “tuck”25 model12. In one animal, a postoperative thrombus sponta-
neously dissolved in the desirudin group. In contrast to low-dose hirudin (250 μ g/ml), intraluminal injection 
of high-dose hirudin (750 μ g/ml) significantly decreased the thrombosis rate of traumatised rabbit ear arteries 
in comparison with saline solution11. Our study corroborates the positive effect of hirudin on flap perfusion. 
In the present study, we used lepirudin (Reflundan®), another synthetic hirudin derivative. This substance was 
withdrawn from the market in 2012, but we used some remaining samples, accepting the limited transferability 
to clinical practice. With a vitality rate of 58%, the amount of vital tissue was comparable to that resulting from 
treatment with clopidogrel (63.5%) and was significantly higher compared to the groups treated with saline solu-
tion, pentoxifylline I and HES. Since the drug intake has to be commenced two to four weeks prior to the surgical 
procedure to be fully effective43, the positive effects of lepirudin might have been even higher if the therapy had 
been commenced earlier. Hirudin also seems to have a positive, load-reducing effect on the venous system and 
improves microcirculation56. In accordance with the findings of previous studies, in our experimental model, the 
flow and oxygen levels in the microcirculation tended to be higher in the lepirudin group in comparison with 
saline controls, but no statistical analysis was performed.
The xanthin derivative pentoxifylline is a competitive nonselective photodiesterase inhibitor that reduces 
inflammation and innate immunity57. In addition, pentoxifylline increases the blood flow by inducing vasodila-
tation, inhibits platelet aggregation, reduces the concentration of fibrin and increases the deformability of eryth-
rocytes (known as a haemorheological effect)45,51. A positive influence on the microcirculation and oxygenation 
of free flaps has also been reported5,13,58. Murthy et al.13 observed significantly higher vitality rates of rat epigastric 
flaps and higher patency rates of the supplying femoral/epigastric arteries after daily administration of pentoxi-
fylline or low molecular weight heparin, while a combination of the two drugs had no significant impact on flap 
survival. In their study, a thrombogenic environment was created by traumatizing the vessel wall with a vascular 
clip. The fact that the combination therapy did not yield better results than controls might be attributable to 
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haematoma formation under the skin island caused by the double anticoagulation13. The timing of the initial 
pentoxifylline dose seems to have an impact as well. For example, when the drug was administered every 12 hours 
in all study groups in a rat random skin model5, pentoxifylline only had a significant impact on flap survival if the 
first dose was administered directly before surgery. In contrast to this observation, the initiation of pentoxifylline 
therapy 14 days prior to surgery tended to have better results than administration directly prior to surgery in our 
study, but the difference was not statistically significant. Confirming the results of other studies that have indicated 
a positive effect on microcirculation5,13,58, pentoxifylline showed the highest flow and velocity values on day 7, 
but only when the initial dose was administered directly prior to surgery. However, the vitality rate was among 
the lowest of all experimental groups and did not differ from that of the saline controls. One reason for this poor 
result may have been that the pentoxifylline dose used in our study was too low to have an effect on flap viability. 
The dose used in our study was comparable to the human dose recommendation calculated down to match the 
weight of the animal, whereas the daily pentoxifylline dose used in the aforementioned studies was approximately 
four to five times higher.
Hydroxyethyl starch (HES), is a nonionic starch derivative. Due to its high water-binding capacity, which 
leads to a fluid shift from the interstitium to the intra-vascular space, HES is considered to be a plasma expander. 
In accordance with the Hagen-Poiseuille equation, HES increases the blood flow by causing haemodilution 
and a reduction of the blood viscosity. A direct platelet-inhibiting effect of HES has also been reported59. In a 
“crush-avulsion-injury” model, the patency rate of rabbit central ear arteries was significantly higher after the 
administration of dextran, another plasma expander14. However, no significant difference could be observed 
when the central ear arteries were conventionally severed and anastomosed. In a similar experiment, dextrane 
had only a temporary effect on the vessel patency during the first two hours after anastomosis. No long-term 
effect was observed15. Since HES was used instead of dextrane in our study, and the primary outcome was flap 
viability, a direct comparison with the aforementioned studies is not possible. Similar to dextran, however, HES 
showed a high blood flow (comparable with the baseline values) immediately after surgery, whereas the postop-
erative blood flow had dropped significantly in most of the other study groups. However, no positive long-term 
effect was observed, comparable with the aforementioned dextrane studies. HES had no positive impact on flap 
viability in our model.
All types of antithrombotics show trends towards increased risks of haematoma, regardless of the reg-
imen. Heparin and ASA seem to increase this risk significantly in the clinical setting, as shown by a recent 
meta-analysis24. The authors argue that, given that haematomas can cause pedicle thrombosis and flap conges-
tion, a correlation between flap haematoma and flap failure can affect the results24. Our results corroborate these 
findings. The risk of haematoma was significantly higher in all experimental groups in comparison with saline 
controls. The most severe cases of haematoma were detected in the clopidogrel, lepirudin and clexane groups, 
and haematoma formation had a significant negative impact on flap survival in the clopidogrel group. Wound 
haematomas were also observed in the control group but less often, and they were far less severe. Interestingly, 
microcirculation appeared to be unaffected by haematoma formation.
Flap losses after microvascular free flap transfer occur in 3.8% of cases60, and another 7.5%60 of flaps develop 
partial necrosis that can lead to wound infections, revision surgeries, prolonged hospital stays, inferior aesthetic 
and functional results and high economic costs. Our results add to the body of evidence indicating that the use of 
antithrombotic agents, especially the use of clopidogrel, has a positive effect on skin and tissue perfusion, which 
could be beneficial in the treatment of critically perfused flaps. Our results also impressively demonstrated the 
other side of the coin: there was an increased incidence of postoperative bleeding and haematoma formation, 
especially after clopidogrel treatment. Unfortunately, the most potent drug in our study also seems to be the 
most dangerous one with regard to postoperative complications. In light of these observations, the clinical use of 
antithrombotics to improve flap viability must be critically challenged, and the question needs to be raised as to 
whether the potential benefits of these pharmaceutical agents outweigh the higher risk of bleeding complications 
associated with their use.
Continued clopidogrel monotherapy among patients undergoing invasive procedures such as cardiac61 or spi-
nal surgery62 can lead to potentially life-threatening complications. However, minor surgical interventions, such 
as oral surgery or local flap surgery under continued clopidogrel treatment, are either not associated with a high 
risk for postoperative complications63,64, or these complications can be managed with simple local measures63–65. 
Notably, postoperative dual platelet inhibition (clopidogrel and acetylsalicylic acid), as routinely performed 24 
to 48 hours after cardiac surgery, does not cause any significant increase in bleeding risk when compared with 
acetylsalicylic acid monotherapy66.
With these findings in mind, we conclude that postoperative clopidogrel treatment is justified for minor inter-
ventions involving local flaps and may have a positive influence on flap perfusion based on our results. The raising 
of microvascular free flaps itself, however, can be considered an invasive procedure and is usually performed in 
conjunction with extended tumour resections. Therefore, the indications for postoperative clopidogrel treatment 
should be restricted to selected cases. As a recent case report67 shows, clopidogrel treatment, even if administered 
days after major surgery, can be beneficial in critically perfused flaps. Riml et al.67 salvaged a critically perfused 
rectus abdominis flap using a combination of clopidogrel and acetylsalicylic acid ten days after free flap trans-
plantation and unsuccessful revision surgery. Although commencing clopidogrel treatment several days after 
major surgery reduces the postoperative risks, the full pharmacological potential of clopidogrel may be lost. With 
3.8% flap losses and another 7.5% of flaps developing partial necrosis after free flap surgery60, it is all the more 
important to identify these cases early. Meticulous preoperative patient assessment can help to identify patients 
with a high risk of flap loss (e.g., severe atherosclerosis, coagulopathy, or a history of flap losses). Perioperative 
close monitoring of flap perfusion using established tools, such as indocyanine green angiography68, non-invasive 
laser Doppler flowmetry and remission spectrophotometry69, alongside clinical evaluations can help to identify 
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critically perfused flaps early in the course of failure. In these high-risk cases, we believe that postoperative 
antithrombotic treatment is justified.
Our study demonstrates that various pharmacological agents positively influence skin perfusion and that 
some (clopidogrel and lepirudin) have the potential to significantly improve flap viability. However, a number 
of limitations should be taken into consideration when interpreting the results of this study. In general, experi-
ments performed in rodents may not accurately predict the results in humans. The doses and frequencies used 
in this study were selected according to recommendations from the literature, or, if no comparable animal study 
existed, were specified according to human dose recommendations. Other doses or combinations of different 
pharmacological agents may lead to different results. Although flaps were raised as perforator-based “free” flaps 
in this study, no microvascular anastomosis was performed to avoid the creation of a thrombogenic environment. 
Therefore, a direct comparison of our model with microvascular free flaps might not be entirely adequate. Our 
model may be more adequately compared with a random skin flap model, in which the amount of tissue necrosis 
directly correlates with the effect of the administered pharmaceutical agent.
This study showed that clopidogrel and hirudin (lepirudin) are effective pharmaceutical agents that sig-
nificantly increase the viability of perforator skin flaps in rats. Our study supports the assumption that many 
antithrombotic drugs also have an additional rheological effect. Our positive results are overshadowed by a sig-
nificantly higher risk of postoperative bleeding complications after antithrombotic therapy, which had a signif-
icant impact on flap viability in the clopidogrel group. This study adds to the body of evidence supporting the 
conclusion that perioperative antithrombotic therapy can have a positive influence on flap survival, but further 
large-scale clinical studies are needed to confirm or disprove these observations and help to decide whether the 
marginal benefits in terms of flap perfusion and viability outweigh the higher risk of bleeding complications.
Methods
All animals were treated and housed in accordance with EU guidelines. The study was approved by the regional 
government (Regierung von Oberbayern, AZ55.2-1-54-2532-129-10) and was conducted in accordance with the 
German Animal Welfare Act. A total of 108 male Wistar rats (280–320 g, Fa. Charles River, Kißlegg, Germany) 
were used. Food and water were provided ad libitum. All surgical procedures were performed under intravenous 
general anaesthesia [100 mg/kg ketamine (Narketan® , Fa. Vétoquinol GmbH, Ravensburg, Germany) and 5 mg/kg 
xylazine (Rompun® , Fa. Bayer Vital GmbH, Leverkusen, Germany)] and aseptic conditions as described else-
where70, and all efforts were made to minimise suffering.
Surgical technique. The epigastric flap was raised as a perforator flap based on a single main perforator 
from the deep inferior epigastric system with a standardised dimension of 4 × 7 cm2, as described elsewhere in 
detail (Fig. 3)27,71. An oversized flap model was selected to detect the possible impact of different pharmaceutical 
agents on the vitality of critically perfused areas of the flap72. After the flap was raised, it was sutured back into the 
wound bed with 6–0 monofilament interrupted sutures (Ethilon®, Ethicon, Norderstedt, Germany).
Figure 3. Clinical aspects of epigastric perforator flaps. Upper left: Raised epigastric flap based on a single 
perforator (white broken circle) after bipolar cautery of the superficial epigastric vessels and all but one deep 
inferior perforator. The remaining perforator was handled with great care to avoid vasospasm. Lower left and 
middle: The same flap on postoperative day 7 after daily clopidogrel treatment. Lower left: In addition to the 
strong, pulsating, main perforator (white circle), several new vessels (black circles) can be observed. Middle: The 
vital flap on day 7 after clopidogrel treatment with almost no necrotic area. The re-established vascular network 
is visible through the skin. Right: Massive haematoma under a necrotic flap on day 7 after clopidogrel treatment.
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Experimental groups. All rats were randomised by a computer-generated list and subdivided into nine 
groups (n = 12). Following a strict protocol, ASA, clopidogrel, unfractioned heparin, low molecular weight hepa-
rin (clexane), hirudin (lepirudin), pentoxifylline or HES was administered (n = 12 each) starting prior to surgery 
and continuing for seven days. Each group was treated perioperatively with either saline solution (control group) 
or an active medication according to the medication protocol depicted in Table 4. The doses and frequencies used 
in this study were selected according to recommendations from the literature, or, if no comparable animal study 
existed, were specified according to human dose recommendations.
Assessment of microcirculation. In addition to observing the flap colour and capillary refill, measure-
ments of the tissue oxygen saturation (SO2 in %), haemoglobin level (Hb, in AU, arbitrary units), blood flow (in 
AU) and velocity (in AU) were non-invasively performed using combined laser Doppler flowmetry and remission 
spectroscopy (O2C, equipped with an LF-2 probe, Lea Medizintechnik, Giessen, Germany). This technique is an 
established procedure used for the assessment of free flaps and has been described elsewhere in detail69. In all 
surgical groups, O2C was performed preoperatively (base value), after the flap was raised and on day 7. All meas-
urements were taken from the central part of the flap and compared to the same area if possible. If necrosis had 
occurred, measurements were taken from the central area of the remaining viable flap tissue instead.
Planimetric measurement of necrotic areas. On postoperative day 7, the rats were put under anaesthe-
sia again, and flap healing was documented using a digital SLR camera (type Nikon Coolpix 8700. Nikon Corp., 
Chiyoda, Tokyo, Japan) mounted in a perpendicular direction to the flap with a tripod. Pictures were analysed 
with respect to vital and necrotic areas. Therefore, the total flap area and necrotic areas were manually circum-
scribed with the help of a graphic tablet, and the cross-sectional area was calculated using the ImageJ software 
program73.
Assessment of postoperative complications. Rats were euthanised while still under deep anaesthe-
sia using a combination of lethal pentobarbital injection (200 mg/kg, Narcoren®, Rhone-Merieux, Laupheim, 
Germany) and bleeding by severing the abdominal aorta. Flaps were raised as described above and all signs of 
haematoma or seroma were documented and scored according to the severity of the complication (“−” = none, 
“(+ )” = very minor, “+ ” = minor, “+ + ” = moderate, “+ + + ” = severe).
Statistics. For the basic statistical analysis, the Prism software (Prism 7 for Mac OS X, Version 7.0a, GraphPad 
Software, Inc., La Jolla, CA, USA) was used. The SPSS software package (SPSS 22, SPSS Inc., Chicago, IL, USA) 
was used for the multivariate analysis. The rate of necrosis was assessed using an ordinary one-way ANOVA 
to determine the significance of differences between groups. Tukey’s multiple comparison testing was used to 
account for the problem of multiple testing. Pearson’s correlation was used to determine whether postoperative 
haematoma formation had a significant influence on the flap viability. Differences were considered to be statisti-
cally significant for a two-sided P value of < 0.05. All data are presented as the mean ± standard deviation (SD). 
All observations were independently evaluated by two investigators blinded to the experimental groups.
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